238 related articles for article (PubMed ID: 17120733)
1. The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.
Ding Y; Ruan Q
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):405-7. PubMed ID: 17120733
[TBL] [Abstract][Full Text] [Related]
2. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
3. The significance of combined CK5/6 and p63 immunohistochemistry in predicting the risks of subsequent carcinoma development in intraductal papilloma of the breast.
Yang Y; Suzuki K; Abe E; Li C; Uno M; Akiyama F; Yamauchi H; Kikuchi M; Ohde S; Deshpande G; Shibahara Y; Nakamura Y; Sasano H
Pathol Int; 2015 Feb; 65(2):81-8. PubMed ID: 25572436
[TBL] [Abstract][Full Text] [Related]
4. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical staining of papillary breast lesions.
Troxell ML; Masek M; Sibley RK
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic utility of CK5/6 and p63 in fine-needle aspiration of the breast lesions diagnosed as proliferative fibrocystic lesion.
Al-Maghraby H; Ghorab Z; Khalbuss W; Wong J; Silverman JF; Saad RS
Diagn Cytopathol; 2012 Feb; 40(2):141-7. PubMed ID: 22246930
[TBL] [Abstract][Full Text] [Related]
7. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best.
Reisenbichler ES; Adams AL; Hameed O
Am J Clin Pathol; 2013 Dec; 140(6):767-79. PubMed ID: 24225742
[TBL] [Abstract][Full Text] [Related]
8. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
9. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
10. Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.
Sailer V; Lüders C; Kuhn W; Pelzer V; Kristiansen G
Virchows Arch; 2015 Jul; 467(1):67-70. PubMed ID: 25850754
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
14. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
Shekhar MP; Kato I; Nangia-Makker P; Tait L
Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of immunocytochemistry using a Breast Marker antibody cocktail targeting P63/cytokeratin7/18/cytokeratin5/14 for fine needle aspiration of the breast: a retrospective cohort study of 139 cases.
Tanaka S; Kanomata N; Teramura K; Wakita K; Kunihisa T; Yano Y; Moriya T; Hayashi Y
Cytopathology; 2016 Dec; 27(6):465-471. PubMed ID: 27060708
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemical staining in breast papillary neoplasms of cytokeratin 5/6 and p63 in core needle biopsies and surgical excisions.
Koo JS; Kim MJ; Kim EK; Park BW
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):108-15. PubMed ID: 22553810
[TBL] [Abstract][Full Text] [Related]
17. The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology.
Reisenbichler ES; Ross JR; Hameed O
Ann Diagn Pathol; 2014 Dec; 18(6):313-8. PubMed ID: 25224390
[TBL] [Abstract][Full Text] [Related]
18. [The value of immunohistochemical expression of Ki-67 and CD34 in differentiating ductal carcinoma in situ from ductal carcinoma in situ-like invasive breast cancer].
Pan XY; Wu JK; Lang ZQ; Qu L; Jiang L
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):838-842. PubMed ID: 36097899
[No Abstract] [Full Text] [Related]
19. The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies.
Nofech-Mozes S; Holloway C; Hanna W
Int J Surg Pathol; 2008 Oct; 16(4):399-406. PubMed ID: 18499686
[TBL] [Abstract][Full Text] [Related]
20. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Moriya T
J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
